Axovant Sciences, a newly formed biotech developing a late-stage Alzheimer's therapy acquired from GSK, raised $315 million by offering 21 million shares at $15, the high end of the range of $13 to $15. Axovant Sciences plans to list on the NYSE under the symbol AXON. Axovant Sciences initially filed confidentially on 3/24/2015. Jefferies & Co., Evercore Partners and RBC Capital Markets acted as lead managers on the deal.
